Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mental Illness AND Schizophrenia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    114 result(s) found for: Mental Illness AND Schizophrenia. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2007-000800-34 Sponsor Protocol Number: H8Y-MC-HBBI Start Date*: 2007-08-14
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia.
    Medical condition: Patients must have a diagnosis of Schizophrenia as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Disorganized, 295.10; Catatonic, 295.20; Paranoid, 295....
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039638 Schizophrenia, disorganised type PT
    9.1 10039637 Schizophrenia, catatonic type PT
    9.1 10039639 Schizophrenia, paranoid type PT
    9.1 10039640 Schizophrenia, residual type PT
    9.1 10052792 Schizophrenia, undifferentiated type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000278-22 Sponsor Protocol Number: gisas001 Start Date*: 2007-03-01
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: GiSAS trial aripiprazole, olanzapine and haloperidol in the long term treatment of schizophrenia.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037175 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003867-36 Sponsor Protocol Number: 2286/2007 Start Date*: 2007-07-18
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: PILOT STUDY OF PHARMACOGENETICS, CLINICAL EFFICACY AND TOLERABILITY OF CLOZAPINE IN PATIENTS AFFECTED BY SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDERS AND BIPOLAR DISORDERS WITH PSYCHOTIC FEATURES
    Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDERS AND BIPOLAR DISORDERS WITH PSYCHOTIC FEATURES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037175 Psychiatric disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022181-28 Sponsor Protocol Number: 13639A Start Date*: 2011-02-07
    Sponsor Name:H. Lundbeck A/S
    Full Title: A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039638 Schizophrenia, disorganised type PT
    14.0 10037175 - Psychiatric disorders 10039639 Schizophrenia, paranoid type PT
    14.0 10037175 - Psychiatric disorders 10052792 Schizophrenia, undifferentiated type PT
    14.0 10037175 - Psychiatric disorders 10039637 Schizophrenia, catatonic type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013028-21 Sponsor Protocol Number: ------ Start Date*: 2009-10-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: USE OF CLINICAL AND INTERMEDIATE PHENOTYPES TO ASSESS RESPONSE TO QUETIAPINE: THE ROLE OF PUTATIVE CAUSATIVE GENES
    Medical condition: schizophrenia using the Structured Clinical Interview for Diagnosis (SCID) for the Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV);
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037175 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004835-10 Sponsor Protocol Number: R092670SCH3015 Start Date*: 2016-03-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10039636 Schizophrenia simple PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) DK (Completed) GR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002538-38 Sponsor Protocol Number: 331-10-231 Start Date*: 2011-10-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
    Medical condition: Acute Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002513-11 Sponsor Protocol Number: 331-10-230 Start Date*: 2012-01-09
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia
    Medical condition: Acute Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000213-19 Sponsor Protocol Number: 99824 Start Date*: 2005-03-08
    Sponsor Name:Lundbeck SA
    Full Title: Sertindole versus risperidone safety outcome study: A randomised, partially-blinded, parallel-group, active-controlled, post-marketing study
    Medical condition: Schizophrenic patients most recently treated with antipsychotics other than sertindole or risperidone, requiring a new prescription for an antipsychotic, and without any contraindications for eithe...
    Disease: Version SOC Term Classification Code Term Level
    7 10037175 Psyc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-000576-16 Sponsor Protocol Number: R076477PSZ3001 Start Date*: 2012-03-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizo...
    Medical condition: Adolescent Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020185-19 Sponsor Protocol Number: KP7242114 Start Date*: 2011-05-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Optimization of Treatment and Management of Schizophrenia in Europe
    Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA)
    Trial results: View results
    EudraCT Number: 2017-001941-28 Sponsor Protocol Number: R092670PSY3015 Start Date*: 2018-02-28
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002093-34 Sponsor Protocol Number: NW-3509/020/III/2021 Start Date*: 2021-11-12
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre...
    Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000577-38 Sponsor Protocol Number: PSZ-3002 Start Date*: 2007-08-16
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia
    Medical condition: Adolescents Schizphrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) EE (Completed) PL (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001441-26 Sponsor Protocol Number: 12450A Start Date*: 2009-04-01
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.
    Medical condition: Lu AE58054 is under development by H.Lundbeck A/S as an anti-psychotic in the treatment of schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    9.1 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017024-82 Sponsor Protocol Number: HSJD-EPEP09 Start Date*: 2012-01-02
    Sponsor Name:FUNDACIÓN SANT JOAN DE DEU
    Full Title: Clinical and neuropsychological factors associated with second generation antipsychotic response in patients diagnosed with first episode of early onset schizophrenia spectrum disorders
    Medical condition: First episode of early onset schizophrenia spectrum disorders
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10040705 Simple schizophrenia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004064-35 Sponsor Protocol Number: Start Date*: 2018-04-17
    Sponsor Name:Southern Health NHS Foundation Trust
    Full Title: Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study
    Medical condition: Schizophrenia, schizoaffective disorder or first episode psychosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-000418-13 Sponsor Protocol Number: M10-855 Start Date*: 2012-12-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
    Medical condition: Cognitive Deficits in Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013020-23 Sponsor Protocol Number: RAA09-002 Start Date*: 2010-03-23
    Sponsor Name:King's College London
    Full Title: A Pilot study of cognitive enhancer and cognitive training combination – Testing a therapeutic paradigm for cognitive impairment in schizophrenia
    Medical condition: Cognitive impairment associated with schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003343-29 Sponsor Protocol Number: ACP-103-064 Start Date*: 2019-11-15
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed) BG (Completed) ES (Ongoing) LT (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 10:01:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA